ARTICLE | Company News
VGNX, NGEN in MTHFR deal
November 6, 2001 8:00 AM UTC
Variagenics (VGNX) granted Nanogen (NGEN) non-exclusive rights to develop home brew and analyte specific reagent tests to assess thrombo-embolic disease risk using VGNX's methylenetetrahydrofolate red...